Functions of miR-1 and miR-133a during the postnatal development of masseter and gastrocnemius muscles
- 251 Downloads
The present study investigated the function of miR-1 and miR-133a during the postnatal development of mouse skeletal muscles. The amounts of miR-1 and miR-133a were measured in mouse masseter and gastrocnemius muscles between 1 and 12 weeks after birth with real-time polymerase chain reaction and those of HDACs, MEF2, MyoD family, MCK, SRF, and Cyclin D1 were measured at 2 and 12 weeks with Western blotting. In both the masseter and gastrocnemius muscles, the amount of miR-1 increased between 1 and 12 weeks, whereas the amount of HADC4 decreased between 2 and 12 weeks. In the masseter muscle, those of MEF2, MyoD, Myogenin, and MCK increased between 2 and 12 weeks, whereas, in the gastrocnemius muscle, only those of MRF4 and MCK increased. The extent of these changes in the masseter muscle was greater than that in the gastrocnemius muscle. The amounts of miR-133a, SRF, and Cyclin D1 did not change significantly in the masseter muscle between 1 and 12 weeks after birth. By contrast, in the gastrocnemius muscle, the amounts of miR-133a and Cyclin D1 increased, whereas that of SRF decreased. Our findings suggest that the regulatory pathway of miR-1 via HDAC4 and MEF2 plays a more prominent role during postnatal development in the masseter muscle than in the gastrocnemius muscle, whereas that of miR-133a via SRF plays a more prominent role in the gastrocnemius muscle than in the masseter muscle.
KeywordsmiRNA HDAC4 MEF2 SRF Skeletal muscles
This study was supported by JSPS KAKENHI Grant Number 24792313 (MN), 20592190, 25463201 (AY), and 23593053 (YA). We thank Dr. Jim Cahill of ON-LINE EDIT Science Communications for help in the preparation of this manuscript.
- 7.Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, Richardson JA, Bassel-Duby R, Olson EN (2007) An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci USA 104:20844–20849. doi: 10.1073/pnas.0710558105 PubMedCentralCrossRefPubMedGoogle Scholar
- 17.Torella D, Iaconetti C, Catalucci D, Ellison GM, Leone A, Waring CD, Bochicchio A, Vicinanza C, Aquila I, Curcio A, Condorelli G, Indolfi C (2011) MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res 109:880–893. doi: 10.1161/CIRCRESAHA.111.240150 CrossRefPubMedGoogle Scholar
- 18.Gao S, Wassler M, Zhang L, Li Y, Wang J, Zhang Y, Shelat H, Williams J, Geng YJ (2014) MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis 232:171–179. doi: 10.1016/j.atherosclerosis.2013.11.029 PubMedCentralCrossRefPubMedGoogle Scholar
- 25.Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, Hopkinson NS, Polkey MI, Kemp PR (2012) Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax 67:26–34. doi: 10.1136/thoraxjnl-2011-200309 PubMedCentralCrossRefPubMedGoogle Scholar
- 26.Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, Fischer CP, Roder K, Babraj J, Wahlestedt C, Hutvagner G, Pedersen BK, Timmons JA (2010) Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2:9. doi: 10.1186/gm130 PubMedCentralCrossRefPubMedGoogle Scholar
- 27.Al-Khalili L, Chibalin AV, Yu M, Sjödin B, Nylén C, Zierath JR, Krook A (2004) MEF2 activation in differentiated primary human skeletal muscle cultures requires coordinated involvement of parallel pathways. Am J Physiol Cell Physiol 286:1410–1416. doi: 10.1152/ajpcell.00444.2003 CrossRefGoogle Scholar